A Phase Ib, Open-label, Multicenter Study of Oral LXH254 in Combination With Oral LTT462 in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer

Trial Profile

A Phase Ib, Open-label, Multicenter Study of Oral LXH254 in Combination With Oral LTT462 in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs LTT 462 (Primary) ; LXH 254 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2017 Planned primary completion date changed from 31 Dec 2018 to 30 Sep 2017.
    • 17 May 2017 Planned primary completion date changed from 30 Sep 2017 to 31 Dec 2018.
    • 24 Apr 2017 Planned End Date changed from 13 Dec 2019 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top